Browsing Molecular Pathology by title
Now showing items 65-84 of 888
-
Anal squamous cell carcinoma in a high HIV prevalence population.
(SPRINGER, 2021-02-11)Anal Squamous Cell Carcinoma (ASCC) is a rare cancer that has a rapidly increasing incidence in areas with highly developed economies. ASCC is strongly associated with HIV and there appears to be increasing numbers of ... -
Analysis of Circulating Cell-Free DNA Identifies Multiclonal Heterogeneity of BRCA2 Reversion Mutations Associated with Resistance to PARP Inhibitors.
(AMER ASSOC CANCER RESEARCH, 2017-09-01)Approximately 20% of metastatic prostate cancers harbor mutations in genes required for DNA repair by homologous recombination repair (HRR) such as BRCA2 HRR defects confer synthetic lethality to PARP inhibitors (PARPi) ... -
Analysis of novel therapeutic options for adenoid cystic carcinoma of the salivary glands
(Institute of Cancer Research (University Of London), 2021-04-30)Adenoid cystic adenocarcinoma (ACC) of the salivary glands is characterised by slow growth, frequent metastasis and low survival rates. ACC is resistant to conventional chemotherapy and currently, no systemic agent has ... -
Analysis of tumour ecological balance reveals resource-dependent adaptive strategies of ovarian cancer.
(ELSEVIER, 2019-10-21)BACKGROUND: Despite treatment advances, there remains a significant risk of recurrence in ovarian cancer, at which stage it is usually incurable. Consequently, there is a clear need for improved patient stratification. ... -
Analytical validation of a standardised scoring protocol for Ki67 immunohistochemistry on breast cancer excision whole sections: an international multicentre collaboration.
(2019-08)Aims The nuclear proliferation marker Ki67 assayed by immunohistochemistry has multiple potential uses in breast cancer, but an unacceptable level of interlaboratory variability has hampered its clinical utility. The ... -
Analytical Validation of Multiplex Biomarker Assay to Stratify Colorectal Cancer into Molecular Subtypes.
(NATURE PORTFOLIO, 2019-05-21)Previously, we classified colorectal cancers (CRCs) into five CRCAssigner (CRCA) subtypes with different prognoses and potential treatment responses, later consolidated into four consensus molecular subtypes (CMS). Here ... -
Androgen receptor expression in circulating tumour cells from castration-resistant prostate cancer patients treated with novel endocrine agents.
(NATURE PUBLISHING GROUP, 2015-03-31)BACKGROUND: Abiraterone and enzalutamide are novel endocrine treatments that abrogate androgen receptor (AR) signalling in castration-resistant prostate cancer (CRPC). Here, we developed a circulating tumour cells (CTCs)-based ... -
Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study.
(OXFORD UNIV PRESS, 2017-07-01)BACKGROUND: There is an urgent need to identify biomarkers to guide personalized therapy in castration-resistant prostate cancer (CRPC). We aimed to clinically qualify androgen receptor (AR) gene status measurement in ... -
Androgen receptor-modulatory microRNAs provide insight into therapy resistance and therapeutic targets in advanced prostate cancer.
(SPRINGERNATURE, 2019-07-11)Androgen receptor (AR) signalling is a key prostate cancer (PC) driver, even in advanced 'castrate-resistant' disease (CRPC). To systematically identify microRNAs (miRs) modulating AR activity in lethal disease, ... -
Antigen retrieval and clearing for whole-organ immunofluorescence by FLASH.
(NATURE RESEARCH, 2020-11-27)Advances in light-sheet and confocal microscopy now allow imaging of cleared large biological tissue samples and enable the 3D appreciation of cell and protein localization in their native organ environment. However, the ... -
Applications of intertumoural, intratumoural and intermolecular heterogeneity for personalised medicine in colorectal cancer
(Institute of Cancer Research (University Of London), 2020-03-31)Colorectal cancer (CRC) is a heterogeneous disease, both at the molecular level and in the context of patients' responses to treatment. Few biomarkers are currently in place that can help to stratify patients in the clinical ... -
ARAF suppresses ERBB3 expression and metastasis in a subset of lung cancers.
(2022-03-18)RAF kinases are highly conserved serine/threonine kinases, and among the three RAF isoforms (ARAF, BRAF, and CRAF), the pathophysiological relevance of ARAF is not well defined. Here, we show that patients with lung cancer ... -
ARID1A influences HDAC1/BRD4 activity, intrinsic proliferative capacity and breast cancer treatment response.
(NATURE PORTFOLIO, 2020-02-01)Using genome-wide clustered regularly interspaced short palindromic repeats (CRISPR) screens to understand endocrine drug resistance, we discovered ARID1A and other SWI/SNF complex components as the factors most critically ... -
Artificial intelligence and digital pathology: Opportunities and implications for immuno-oncology.
(ELSEVIER, 2021-02-06)The field of immuno-oncology has expanded rapidly over the past decade, but key questions remain. How does tumour-immune interaction regulate disease progression? How can we prospectively identify patients who will benefit ... -
Assessing the effect of obesity-related traits on multiple myeloma using a Mendelian randomisation approach.
(NATURE PUBLISHING GROUP, 2017-06-16) -
Assessment of 3D MINFLUX data for quantitative structural biology in cells.
(NATURE PORTFOLIO, 2023-01-01) -
Assessment of intratumor immune-microenvironment in colorectal cancers with extranodal extension of nodal metastases.
(BMC, 2018-09-06)BACKGROUND: No data is available on the molecular background of the extra-nodal extension (ENE) of lymph node metastasis (LN) in colorectal cancer (CRC). METHODS: A series of 22 ENE-positive CRCs was considered and three ... -
Assessment of Ki67 in Breast Cancer: Updated Recommendations from the International Ki67 in Breast Cancer Working Group.
(2020-12-28)Ki67 immunohistochemistry, commonly used as a proliferation marker in breast cancer, has limited value for treatment decisions due to questionable analytical validity. The International Ki67 Working Group (IKWG) consensus ... -
Assessment of the contribution of the IHC4+C score to decision making in clinical practice in early breast cancer.
(SPRINGERNATURE, 2012-05-22)BACKGROUND: The immunohistochemical (IHC) 4+C score is a cost-effective prognostic tool that uses clinicopathologic factors and four standard IHC assays: oestrogen receptor (ER), PR, HER2 and Ki67. We assessed its utility ... -
Assessment of the Molecular Heterogeneity of E-Cadherin Expression in Invasive Lobular Breast Cancer.
(MDPI, 2022-01-07)Mutations and loss of E-cadherin protein expression define the vast majority of invasive lobular carcinomas. In a subset of these cases, the heterogeneous expression of E-cadherin is observed either as wild-type (strong ...